Working… Menu

Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration (FUROPHARM-HF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02350725
Recruitment Status : Completed
First Posted : January 30, 2015
Last Update Posted : June 27, 2018
Information provided by (Responsible Party):
scPharmaceuticals, Inc.

Brief Summary:
The purpose of this pilot study is to investigate the pharmacodynamic and pharmacokinetic parameters of a novel furosemide formulation administered subcutaneously as compared to oral furosemide.

Condition or disease Intervention/treatment Phase
Heart Failure Drug: Furosemide injection solution for subcutaneous administration (80 mg) Drug: Oral Furosemide tablets (80 mg) Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Center, Randomized, Open-label, Cross-over Exploratory Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response to a Subcutaneous Administration or Oral Administration of Furosemide in Subjects With Heart Failure Presenting With Chronic Fluid Overload
Study Start Date : December 2014
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
Drug Information available for: Furosemide

Arm Intervention/treatment
Experimental: Group 1
Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours followed by Oral Furosemide tablets (80 mg) in second period.
Drug: Furosemide injection solution for subcutaneous administration (80 mg)
Drug: Oral Furosemide tablets (80 mg)
Experimental: Group 2
Oral Furosemide tablets (80 mg) followed by Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours in second period.
Drug: Furosemide injection solution for subcutaneous administration (80 mg)
Drug: Oral Furosemide tablets (80 mg)

Primary Outcome Measures :
  1. Diuresis and natriuresis [ Time Frame: 8 hours ]
    Statistical summaries with a graphical presentation will show mean and individual diuresis and natriuresis time profiles such as time to first void, volume of first void, diuresis and natriuresis measured at 60 minute intervals up to 480 minutes following furosemide injection solution for subcutaneous administration or oral tablets. The diuretic response will be compared between therapies using t-tests or Wilcoxon test.

Secondary Outcome Measures :
  1. Body Water Content [ Time Frame: 8 hours ]
    The correlation (Pearson coefficient) between bioimpedance (body water content) and diuresis will be investigated including bioimpedance measurement of fluid overload as a predictor diuretic response.

  2. Pharmacokinetic profiles [ Time Frame: 8 hours ]
    A graphical presentation showing mean and individual plasma furosemide concentration-time profiles for comparison between subcutaneous or oral administration. Plasma furosemide concentration-time data will be analyzed using a non-compartmental method and population PK approach (non-linear mixed-effect model). Furosemide concentrations will be summarized using descriptive statistics (including N, mean, standard deviation (SD), coefficient of variation (CV%), median, minimum and maximum) for each treatment.

  3. Cardiac Markers (NTpro-BNP, hs-Trop T, galectin-3) [ Time Frame: 8 hours ]
    Correlation methods to investigate interaction between cardiac makers (NTpro-BNP, hs-Trop T, galectin-3) and pharmacodynamic parameters (diuresis and natriuresis).

  4. Dypsnea Scores on Visual Analog Scale and Likert Scale [ Time Frame: 8 hours ]
    Dyspnea score (Dyspnea Visual Analog Scale and Likert Scale), the New York Heart Association (NYHA) Functional Classification and thirst distress and grading assessments by subjects in response to subcutaneous or oral administration.

  5. Injection site reaction on Draize Scale and Visual Analog Pain Scale [ Time Frame: 8 hours ]
    Visual inspection of injection site, 5-point Draize Scale and Visual Analog pain assessment recorded during subcutaneous administration.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent obtained before any assessment is performed
  • Male and female subjects ≥18 years of age, with body weight <120 kg and body mass index (BMI) <30 kg/m2
  • Female subjects must be at least 2 years post-menopausal
  • Participant must have been on oral furosemide (40 mg oid or bid) or therapeutic equivalent (bumetanide 1 mg oid or bid) for a period 90 days before the first dose of study medication
  • History of chronic heart failure according to 2012 ESC guidelines with presence of moderate symptoms of chronic fluid overload. Chronic fluid overload is defined as presence of stable signs and symptoms of heart failure and congestion, like dyspnea at mild exertion or minimal exertion, pulmonary congestion and/or peripheral edema at the time of presentation in combination with elevated levels on natriuretic peptides (NT-proBNP > 300 ng/L)
  • In the opinion of the investigator, able to participate in the study

Exclusion Criteria:

  • Acute Decompensated Heart Failure (ADHF) or recent history of ADHF or significant worsening in their HF symptoms (within prior 2 weeks)
  • Contraindication to furosemide
  • Systolic BP (SBP) < 90 mm Hg
  • Temperature > 38°C (oral or equivalent) or sepsis or active infection requiring i.v. anti-microbial treatment
  • Serum sodium < 130 mmol/L and Serum potassium < 3.0 mmol/L
  • Current or planned (throughout the completion of study drug infusion) treatment with any i.v. therapies, including inotropic agents, vasopressors, levosimendan, nesiritide or analogues; or mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device)
  • History of gastric or intestinal surgery that may affect absorption of oral medication
  • Presence or need for urinary catheterization
  • Current or planned ultrafiltration, hemofiltration, or dialysis
  • Impaired renal function defined as an estimated glomerular filtration rate (eGFR) on admission < 30 mL/min/1.73 m2 will be calculated as per standard at local laboratory
  • Administration of intravenous radiographic contrast agent within 72 hours prior to screening or acute contrast-induced nephropathy at the time of screening
  • Major surgery within 30 days prior to screening
  • Administration of an investigational drug or implantation of investigational device, or participation in another trial, within 30 days before screening
  • Inability to follow instructions or comply with procedures
  • Any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02350725

Layout table for location information
University Medical Center Groningen
Groningen, Netherlands
Sponsors and Collaborators
scPharmaceuticals, Inc.
Layout table for investigator information
Principal Investigator: Rudolf A. de Boer, MD, PhD University Medical Center Groningen

Additional Information:
Layout table for additonal information
Responsible Party: scPharmaceuticals, Inc. Identifier: NCT02350725     History of Changes
Other Study ID Numbers: SCP-01-001
2014-002546-49 ( EudraCT Number )
First Posted: January 30, 2015    Key Record Dates
Last Update Posted: June 27, 2018
Last Verified: December 2014
Keywords provided by scPharmaceuticals, Inc.:
Chronic Fluid Overload
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Pharmaceutical Solutions
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action